Wegovy (semaglutide) Injection

Wegovy (semaglutide)

Wegovy® is a prescription injectable medication used for chronic weight management in adults and adolescents with obesity or who are overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol). It contains semaglutide, a GLP-1 receptor agonist, which works by regulating appetite and calorie intake, helping users feel full longer and reduce food consumption.

Wegovy is administered once weekly via subcutaneous injection and should be used along with a reduced-calorie diet and increased physical activity.

Approved Uses:

• Adults with a BMI ≥30 (obesity), or a BMI ≥27 (overweight) with at least one weight-related health condition

• Adolescents aged 12 years and older with BMI ≥95th percentile for age and sex

Key Benefits:

• Supports significant, sustained weight loss

• Mimics natural GLP-1 hormone to control hunger and improve satiety

• Once-weekly injection for convenience and adherence

• May also improve markers related to cardiometabolic health

Important Safety Information:

Wegovy should not be used with other semaglutide-containing products or other GLP-1 receptor agonists. It is not for use in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). Common side effects may include nausea, diarrhea, vomiting, constipation, and abdominal pain.